This finding suggested that anti-PD-L1 treatment increased the expression of bFGF in LNCaP cells that do not express bFGF, suggesting that this increase in bFGF expression may be one of the mechanisms of immunotherapy resistance in prostate cancer cells with high PD-L1 expression. This evidence concerns the gene FGF2 and prostate cancer.